[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652619":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":40,"responsibleParty":59,"collaborators":63,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":26,"enrollmentInfo":76,"targetDuration":26,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":92,"whyStopped":26,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"University of Chile","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Combined Antioxidant Therapy","EXPERIMENTAL","Participants receive combined antioxidant therapy consisting of ascorbate, N-acetylcysteine, and deferoxamine, initiated before reperfusion and maintained during primary PCI, in addition to standard-of-care treatment for STEMI.",[13],"Drug: Combined antioxidant therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants receive matching placebo infusion initiated before reperfusion and maintained during primary PCI, in addition to standard-of-care treatment for STEMI.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Combined antioxidant therapy","Combined Antioxidant Therapy consisting of ascorbate, N-acetylcysteine and deferoxamine",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Matching placebo infusion administered before reperfusion and during primary PCI.",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Ramon Rodrigo, Prof.","CONTACT","56 9 994454807","rrodrigo@uchile.cl",{"name":37,"role":33,"phone":38,"phoneExt":26,"email":39},"Eduardo Villa, MD","56 9 71427205","eduardo.villa.u@gmail.com",[41],{"facility":42,"status":26,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Hospital San Juan de Dios","Santiago","Santiago Metropolitan","8170000","Chile","CL",{"type":49,"coordinates":50},"Point",[51,52],-70.64827,-33.45694,{"lat":52,"lon":51},[55],{"name":56,"role":33,"phone":57,"phoneExt":26,"email":58},"Ruben Aguayo, MD","56 9 99496985","rubenaguayonayle@gmail.com",{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Ramon Rodrigo","Prof. Ramon Rodrigo",[64],{"name":65,"class":6},"Hospital San Juan de Dios,Chile","100652619","phase-2-combined-antioxidant-therapy-for-acute-myocardial-infarction-100652619",false,"NCT07776288","Combined Antioxidant Therapy for Acute Myocardial Infarction","Pharmacological Protection Against Reperfusion Injury in Patients With Acute Myocardial Infarction: a Phase 2 Randomized Controlled Trial of a Combined Antioxidant Therapy (CAT-AMI Trial)","CAT-AMI","Inclusion Criteria:\n\n* Age 18 years or older\n* First anterior ST-segment elevation myocardial infarction (STEMI)\n* Symptom onset within 6 hours before presentation\n* Eligible for primary percutaneous coronary intervention (PCI)\n* Provision of informed consent by the participant or a legally authorized representative, according to local ethics requirements\n\nExclusion Criteria:\n\n* Prior myocardial infarction\n* Cardiogenic shock, defined as Society for Cardiovascular Angiography and Interventions (SCAI) shock class D or E.\n* Prior thrombolytic therapy for the index event.\n* Chronic kidney disease, defined as serum creatinine greater than 1.5 mg\u002FdL or dialysis.\n* Liver cirrhosis\n* Advanced heart failure, defined as New York Heart Association (NYHA) class III or IV\n* Glucose-6-phosphate dehydrogenase (G6PD) deficiency\n* Nephrolithiasis\n* Life expectancy less than 6 months\n* Implanted cardiac device, including pacemaker, implantable cardioverter-defibrillator, or cardiac resynchronization device\n* Prior coronary artery bypass graft (CABG) surgery\n* Pregnancy\n* Claustrophobia\n* Other contraindications to cardiac magnetic resonance imaging (CMR), according to local protocol","ALL","18 Years",{"count":77,"type":78},46,"ESTIMATED","INTERVENTIONAL",[81],"PHASE2","The goal of this clinical trial is to learn if a combined antioxidant therapy (CAT) can reduce heart damage caused by the return of blood flow after blocked arteries are reopened in adults with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). It will also learn about the safety of this treatment. The main questions it aims to answer are:\n\n1. Does combined antioxidant therapy lower infarct size, measured by cardiac magnetic resonance imaging (CMR), compared with placebo?\n2. Does combined antioxidant therapy improve heart function, blood biomarkers of heart injury, and short-term clinical outcomes?\n3. What problems do participants have when receiving the therapy?\n\nResearchers will compare CAT to placebo (a look-alike infusion with no active drug) to see if the treatment lowers infarct size after STEMI.\n\nParticipants will:\n\n* Be randomly assigned to receive either CAT or placebo\n* Receive the study infusion before and during primary PCI, in addition to standard treatment for STEMI\n* Have blood tests to measure heart injury, oxidative stress, inflammation, and drug levels\n* Undergo cardiac magnetic resonance imaging about 3 to 7 days after STEMI.\n* Be followed for clinical outcomes and safety for 30 days.",[84,85,86],"Acute Myocardial Infarction (AMI)","ST Elevation (STEMI) Myocardial Infarction","Reperfusion Injuries, Myocardial",[88,89,90,91,86],"Antioxidant Therapy","Acute Myocardial Infarction","Randomized Controlled Trial","Oxidative stress","NOT_YET_RECRUITING","2026-08-16",{"date":95,"type":96},"2026-08-20","ACTUAL",{"date":98,"type":78},"2026-09-01",{"date":100,"type":78},"2027-12-31",{"name":5,"class":6},1]